Perineural Injection Therapy: Syringe Contents
For perineural injection therapy, the syringe should contain 5% dextrose in water (D5W), typically administered in volumes of 5-10 mL under ultrasound guidance. This represents the current evidence-based standard for treating peripheral nerve entrapment syndromes and neuropathic pain conditions.
Primary Injectate: 5% Dextrose in Water
5% dextrose (D5W) is the recommended solution for perineural injection therapy, with mounting evidence supporting its efficacy and safety profile 1, 2, 3.
Standard Preparation and Dosing
- Volume: 5-10 mL of 5% dextrose in water 1, 3
- Administration: Single injection under ultrasound guidance 1, 2
- Frequency: Average of 1.7-2.6 injections depending on severity 3
The mechanism appears to involve nerve regeneration and reduction of neural inflammation rather than the temporary blockade seen with local anesthetics 4.
Clinical Evidence Supporting D5W
Superior Long-term Outcomes
D5W demonstrates superior sustained benefit compared to corticosteroids at 4-6 months post-injection 1. In a head-to-head randomized trial for carpal tunnel syndrome:
- D5W showed significantly greater pain reduction and disability improvement from months 4-6 compared to triamcinolone 1
- 88.6% of patients reported effective outcomes (≥50% symptom relief) at 1-3 years follow-up 3
- The treatment required an average of 2.2 injections for sustained benefit 3
Broader Applications
D5W perineural injection has demonstrated efficacy across multiple neuropathic conditions 4:
- Postherpetic neuralgia
- Trigeminal neuralgia
- Peripheral neuropathy
- Ulnar neuropathy at the elbow 2
Notable exception: Complex regional pain syndrome (CRPS) did not show significant improvement with D5W 4.
Alternative: Corticosteroid Injection
While corticosteroids have been used historically, they show limitations compared to D5W 1, 5.
Corticosteroid Preparation (When Used)
- 3 mL triamcinolone acetonide (10 mg/mL) mixed with 2 mL normal saline for a total volume of 5 mL 1, 2
- Administered as single injection under ultrasound guidance 1
Comparative Performance
- Corticosteroids provide initial benefit but shorter duration of effect compared to D5W 1
- Both treatments show similar improvement at 1 month, but D5W maintains superiority at 4-6 months 1, 5
- Concerns exist regarding potential neurotoxicity with corticosteroid perineural injection 1
Important Technical Considerations
What NOT to Include
Do not use lidocaine or other local anesthetics as the primary injectate for perineural injection therapy 4. While lidocaine has been used for nerve blocks, the evidence shows:
- D5W demonstrates better pain reduction trends than 0.5% lidocaine for neuropathic pain 4
- Local anesthetics provide only temporary blockade rather than the regenerative effects of D5W 4
Safety Profile
D5W perineural injection has minimal side effects, with only occasional bruising at injection sites reported 4. This contrasts with corticosteroid concerns about:
- Potential neurotoxicity 1
- Shorter duration of benefit 1
- Patient hesitancy due to steroid adverse effects 5
Clinical Pitfalls to Avoid
- Do not confuse perineural injection therapy with nerve blocks: These are distinct procedures with different mechanisms and injectates 4
- Avoid using unbuffered solutions: The evidence specifically references buffered 5% dextrose for optimal results 4
- Do not expect immediate results: Peak benefit occurs at 4-6 months, not immediately post-injection 1
- Severity matters: More severe cases require additional injections (average 2.6 vs 1.7 for mild cases) 3